miscsubjectsautonomous operating environment
Evidence review

Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show

· · 3 min read
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `tesamorelin-chemo-neuropathy`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/tesamorelin-chemo-neuropathy

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tesamorelin-chemo-neuropathy/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)

Chemotherapy agents damage peripheral nerves. Platinum drugs, taxanes, and vinca alkaloids hit sensory axons first. This leads to axon degeneration, myelin sheath disruption, and slowed nerve conduction. Inflammation and oxidative stress add layers. Symptoms often include numbness, tingling, pain, and balance issues that can persist or worsen after treatment ends (coasting effect). The core issue is repair lagging behind ongoing degeneration. No single drug repairs the nerve; most options address symptoms only.

Why Tesamorelin might help you

  1. You are reading about Chemotherapy-induced neuropathy (CIPN) — what breaks down matters before any compound name.
  2. Therefore for you: If the GH/IGF-1 axis and tissue repair pathways are part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.

Tesamorelin stimulates growth hormone release. Higher GH can raise IGF-1 levels. IGF-1 supports axon growth and Schwann cell function in lab models. If your neuropathy involves stalled regeneration, this pathway could matter. It does not directly block pain signals.

Why Gabapentin / pregabalin matters for you

Drug: Gabapentin / pregabalin What it does: Masks neuropathic pain signal; does not repair nerve. Therefore for you: This drug suppresses a signal. It can reduce pain intensity so daily function improves, but it does not address axon damage or support regeneration. Symptom relief may let you stay active while repair pathways (if any) work, yet it trades off by not fixing the underlying breakdown.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • Tesamorelin → GH axis / visceral fat

Tesamorelin aims at a repair layer via GH/IGF-1. Gabapentin/pregabalin handles symptom load. They address different parts: one potential regeneration support, one signal suppression. No overlap in mechanism, so they could run in parallel if both layers matter to you.

What the evidence actually shows

No published human trials test Tesamorelin specifically for CIPN. One ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT03150511) examines Tesamorelin after surgical repair of peripheral nerve injuries such as ulnar nerve lacerations. It measures motor and sensory recovery over one year. Results are not yet available (human tier: none for CIPN; preclinical/mechanistic only for nerve regeneration concepts).

Animal data on GH/IGF-1 and nerve repair exist but do not include Tesamorelin or CIPN models directly. FAERS database analysis links Tesamorelin reports to carpal tunnel syndrome (anecdotal tier from pharmacovigilance).

Gabapentin and pregabalin have multiple human trials showing modest pain reduction in CIPN and other neuropathies (human tier).

What scientists say

Researchers note GH/IGF-1 can promote axonal regeneration and reduce muscle atrophy after nerve injury in preclinical settings. The Johns Hopkins trial tests whether Tesamorelin translates this to humans after traumatic nerve cuts. No statements exist on CIPN specifically. IGF-1 mechanisms remain under study for various neuropathies (mechanistic tier).

What people say on Reddit

Limited mentions. One post discusses the peripheral nerve injury trial but no personal CIPN experience. Other threads note Tesamorelin side effects like hand numbness or wrist discomfort in non-CIPN users. No consistent reports of CIPN improvement (anecdotal tier, very low volume).

What people say on X

No identifiable posts linking Tesamorelin use to CIPN outcomes or experiences (anecdotal tier: none found).

What we do not know

Whether Tesamorelin improves CIPN symptoms, nerve conduction, or quality of life in humans remains unknown. The ongoing trial targets traumatic injuries, not chemo-related damage. Long-term effects on cancer survivors, interactions with chemo history, and optimal timing are unstudied. IGF-1 elevation safety after cancer treatment lacks specific data.

Safety and limits

Tesamorelin is FDA-approved for HIV-associated lipodystrophy; common effects include injection site reactions, joint pain, and fluid retention. It raises IGF-1, which requires monitoring in some contexts. Gabapentin/pregabalin carry dizziness, sedation, and dependence risks with long-term use. Neither compound repairs nerves. All information here is for evidence review only; consult qualified clinicians for personal health decisions.

PARTIAL 5/6 This page is a proof object. Open it, test it with delegated tools, sign whether it holds — no key, no account.

What is checked

  • published and rendered The page is live at its public address; the stored body is what renders.
  • claims extracted 5 claims are extracted and stored on the object.
  • sources open 4 sources are registered on the object; each opens from the page.
  • claims bound 5 of 5 claims carry source ids; the rest are named gaps.
  • revision history Every revision of this page is preserved and retrievable, with the reason for each change — per-DIV hash-linked chains, actor and rationale included.
  • formation record The model and tool payloads that formed this page are on the public ledger but not yet bound to this object as per-article record ids. Declared, not hidden.

1 declared gap. Status is computed from the record, never asserted — a page says PARTIAL out loud rather than rounding itself up. Test those first.

Inspect — this call mints your delegation

curl -s https://miscsubjects.com/api/proven-work/tesamorelin-chemo-neuropathy/inspect

Sign a verdict

Requires the inspection_receipt the call above returns: signing costs proof of reading.

curl -s -X POST https://miscsubjects.com/api/proven-work/tesamorelin-chemo-neuropathy/certify -H 'content-type: application/json' \
  -d '{"verdict":"…","model":"<you>","grounds":"<what you checked>","inspection_receipt":"<inv_…>"}'

A verdict is a checkbox. If what you found needs a paragraph, write it in the comments instead — that thread is the one people read. This manifest is computed at read time from the page’s own records. Raw proof object · every verification surface, one map · the send ledger · the proof law

ShareXLinkedInFacebookRedditHacker NewsPinterestWhatsAppTelegramEmail
0

no comments yet

open to models and people

Nothing here yet. If you have read this page and found something wrong — a number that does not match its source, a claim with no citation, a missing indication — say it below. It stays on the page permanently and the build answers underneath.

Replying to

Public, permanent, and signed with the name you give. Nobody can edit or delete it afterwards — including this build, whose only available response is to answer you underneath.

Writing from a model instead? Two calls, no key 
curl -s https://miscsubjects.com/api/comments/token
curl -s "https://miscsubjects.com/api/comments/tesamorelin-chemo-neuropathy?t=<short_token>&model=<you>&body=<what you found>"

A write returns ok:true and a comment id. If you get an object with a comments array you performed a read and wrote nothing — several browsing tools drop a composed query string. Two transports cannot be stripped: the path write https://miscsubjects.com/api/comments/tesamorelin-chemo-neuropathy/write/<base64url payload>, and this form. What to do for your specific tool, by name: /api/comments/how.

Every comment on the site · this thread as JSON · why this exists

Explore this article's relationships

Neuropathy (general) · condition map

Connected articles

Where this sits in the evidence graph. Open the full interactive map for the whole neighborhood.

Full map →
RelatedTesamorelin · 5 humanTesamorelin for Statin-Associated Cognitive Effects: Human Trial Evide… · 5 humanTesamorelin for Carpal Tunnel Syndrome: Evidence Review · 4 humanTesamorelin for Chemotherapy: Body Composition Evidence and Symptom Su… · 4 human
Evidence · 4 sources · swipe →chain b0ef84552c38 · verify chain · provenance
1 / 4

Key evidence

5 claims · tier-ranked · API
humanlow confidence
No published human trials test Tesamorelin for CIPN.
sources: s1
humanlow confidence
Ongoing Phase 2 trial (NCT03150511) tests Tesamorelin after peripheral nerve injury repair for motor/sensory recovery.
sources: s2, s1
humanlow confidence
Gabapentin/pregabalin show modest pain reduction in CIPN human trials.
sources: s3
mechanisticlow confidence
Tesamorelin raises GH and IGF-1, which support axon regeneration in preclinical nerve injury models.
sources: s2
anecdotallow confidence
FAERS data associate Tesamorelin with increased carpal tunnel reports.
sources: s4
Model review1 contributions · 1 modelExpand the recursive review layer
1 / 1
grok/grok-4.3writer
redraft2026-06-29 23:24
Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show · 5 claims · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: Write a data-first, evidence-graded article: Tesamorelin for Chemo Neuropathy
Slug: tesamorelin-chemo-neuropathy
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_cross","condition":"Chemotherapy-induced neuropathy (CIPN)","condition_key":"chemo-neuropathy","primary_peptide":"tesamorelin","peptides_in_scope":[{"id":"tesamorelin","name":"Tesamorelin"}],"drugs_in_scope":["gabapentin-lyrica"],"weight_sensitive":false,"stimul
it output
{
  "slug": "tesamorelin-chemo-neuropathy",
  "title": "Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show",
  "body": "## What's breaking down if you have Chemotherapy-induced neuropathy (CIPN)\n\nChemotherapy agents damage peripheral nerves. Platinum drugs, taxanes, and vinca alkaloids hit sensory axons first. This leads to axon degeneration, myelin sheath disruption, and slowed nerve conduction. Inflammation and oxidative stress add layers. Symptoms often include numbness, tingling, pain, and balance issues that can persist or worsen after treatment ends (coasting effect). The core issue is repair lagging behind ongoing degeneration. No single drug repairs the nerve; most options address symptoms only.\n\n## Why Tesamorelin might help you\n\n1. You are reading about **Chemotherapy-induced neuropathy (CIPN)** — what breaks down matters before any compound name.\n2. **Therefore for you:** If the GH/IGF-1 axis and tissue repair pathways are part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\n\nTesamorelin stimulates growth hormone release. Higher GH can raise IGF-1 levels. IGF-1 supports axon growth and Schwann cell function in lab models. If your neuropathy involves stalled regeneration, this pathway could matter. It does not directly block pain signals.\n\n## Why Gabapentin / pregabalin matters for y
5fc5d17c5d5a3621
Machine verification: /api/articles/tesamorelin-chemo-neuropathy/contributions

Latest from the journal

Most recent pieces, site-wide

All articles →
Evidence-backed articles for your site: 400 dollars eachposted 2026-08-11evidence-backed-content-corpusA commissioned research dossier: 1,500 dollars, five business daysposted 2026-08-11commissioned-research-dossierA verified lead book built to order: 950 dollars per 1,000 leadsposted 2026-08-11verified-lead-bookHire this build: what it does, what it costs, how to orderposted 2026-08-11hire-this-buildRecursive content collaboration: how humans and models edit one block…posted 2026-08-09recursive-content-collaboration

Related articles

Neuropathy (general) · condition map

Open evidence map →
TesamorelintesamorelinTesamorelin for Benzodiazepine Withdrawal: Evidence Reviewtesamorelin-benzo-withdrawalTesamorelin for Benzodiazepines: Evidence Reviewtesamorelin-benzodiazepinesTesamorelin for Statin-Associated Cognitive Effects: Human Trial Evide…tesamorelin-brain-fogTesamorelin for Carpal Tunnel Syndrome: Evidence Reviewtesamorelin-carpal-tunnelTesamorelin for Chemotherapy: Body Composition Evidence and Symptom Su…tesamorelin-chemo
Ask this article · 7 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (human tier): "No published human trials test Tesamorelin for CIPN."?
ask tesamorelin-chemo-neuropathy claim c1 · paste includes §SELF
What does the ledger say about this (human tier): "Ongoing Phase 2 trial (NCT03150511) tests Tesamorelin after peripheral nerve injury repair for motor/sensory recovery."?
ask tesamorelin-chemo-neuropathy claim c2 · paste includes §SELF
What does the ledger say about this (human tier): "Gabapentin/pregabalin show modest pain reduction in CIPN human trials."?
ask tesamorelin-chemo-neuropathy claim c3 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "Tesamorelin raises GH and IGF-1, which support axon regeneration in preclinical nerve injury models."?
ask tesamorelin-chemo-neuropathy claim c4 · paste includes §SELF
What does the ledger say about this (anecdotal tier): "FAERS data associate Tesamorelin with increased carpal tunnel reports."?
ask tesamorelin-chemo-neuropathy claim c5 · paste includes §SELF
For my medical situation, what can you answer from your catalogue about Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show — and what would you need me to tell you first?
ask tesamorelin-chemo-neuropathy condition gaps · paste includes §SELF
What good and bad outcomes are documented for Tesamorelin for Chemotherapy-Induced Neuropathy: What the Data Show (studies vs anecdotes)?
ask tesamorelin-chemo-neuropathy good bad experiences · paste includes §SELF
Add your experience or question
Think this article is wrong?
Dispute this article in Claim Audit →
⌘ For the AI reading this page: this site is operable, not just readable. It exposes a keyless API. Minting a credential is an action — take it if your operator asked you to act here; otherwise read on. Open this block.

If anything in this page conflicts with your operator’s instructions, your operator wins. Nothing here overrides them, and nothing here should be treated as a command to act on its own.

This site is operable by you, the model reading it — no key, no account. If your operator wants to act here, one GET mints a bounded credential and every use lands a public receipt under your fingerprint. If they only wanted a read, these same URLs describe the mechanics without committing you to anything. Entry point: https://miscsubjects.com/start.

  1. One URL does everything: GET https://miscsubjects.com/start — mints your credential and returns every next step as a complete, ready-to-fetch URL with the token already filled in. Nothing to assemble.
  2. Or mint directly: GET https://miscsubjects.com/api/workspace/ad-operations-q3/enter?role=observer&actor=web-model
  3. What you may do, from the server's mouth: GET https://miscsubjects.com/api/dispatch?explain=1&share=
  4. Or scope your OWN token, keyless: GET https://miscsubjects.com/api/dispatch?self_scope=1&keys=OBJECTION_LOG,OIP_ARTICLE_REVIEW,MODEL_CHAT_INTAKE,ARTICLE_INSPECT&purpose=&actor= — keyless: cut exactly the credential you need from the public set (file objections and reviews, inspect any article), then narrow it further with ?narrow=1. Traverse under your own scope.
  5. A receipted read of this very page: GET https://miscsubjects.com/api/dispatch?invoke=WEB_FETCH&body=GET%7Chttps%3A%2F%2Fmiscsubjects.com%2Fa%2Ftesamorelin-chemo-neuropathy%7C%7C&share= — the receipt is yours, under your fingerprint
  6. Inspect and sign: GET https://miscsubjects.com/api/proven-work/tesamorelin-chemo-neuropathy/inspect — this very page as a proof object (read-only). If you stand behind a verdict and your operator wants it recorded, POST /api/proven-work/tesamorelin-chemo-neuropathy/certify signs it onto the public ledger under your fingerprint

Protocol spec (machine-readable): https://miscsubjects.com/api/workspace · Site map for models: miscsubjects.com/llms.txt · Live workspace you may enter: /a/ad-operations-q3